Skip to content

SPI-guided Analgesia During FESS for Intraoperative Blood Loss

Comparative Study of Influence of Surgical Pleth Index Guided Total Intravenous Anaesthesia (TIVA) or Volatile Anaesthesia Using Sevoflurane or Desflurane on the Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03417180
Acronym
FESSSPI
Enrollment
120
Registered
2018-01-31
Start date
2018-09-01
Completion date
2023-07-15
Last updated
2022-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscopic Sinus Surgery

Keywords

Surgical Pleth Index (SPI), Intraoperative Blood Loss (IBL), Boezaart Bleeding Scale (BBS), Spectral Entropy (SE), Adequacy of Anaesthesia (AoA), Total Intravenous Anaesthesia (TIVA), Sevoflurane, Desflurane

Brief summary

The aim of this randomized trial is to assess the utility of Surgical Pleth Index (SPI) for monitoring pain perception intraoperatively and its influence on intraoperative blood loss, quality of surgical field using Boezaart Bleeding Scale (BBS) in patients undergoing functional sinus surgery (FESS) under total intravenous anaesthesia using propofol or volatile anaesthesia using sevoflurane or desflurane

Detailed description

Intraoperative blood loss during FESS constitutes a major problem for a surgeon because it influences quality of surgical field. Each incident of haemorrhage makes the operator stop the procedure in order to bring back the optimal visualization of the intranasal anatomy. In the end it prolongs the time of procedure. Currently, intraoperative blood loss is estimated based on Boezaart Bleeding Scale (BBS) (0 - no bleeding (cadaveric conditions), 1 - Slight bleeding, no suctioning required, 2 - Slight bleeding, occasional suctioning required, 3 - Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed, 4 - Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed, 5 - Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible). Recently, the Surgical Pleth Index (SPI) was added as a surrogate variable showing the nociception-antinociception balance into above mentioned parameters constituting a novel approach in monitoring patients intraoperatively, known as adequacy of anaesthesia (AoA) or tailor-made anaesthesia. SPI\>10 or any SPI\>50, were proposed to constitute the indication for administration of rescue analgesia intraoperatively. This study aims at evaluating utility of SPI-guided analgesia using remifentanil on the intraoperative blood loss, haemodynamic stability and time duration of surgery in patients undergoing functional sinus surgery (FESS) under total intravenous anaesthesia using propofol or volatile anaesthesia using sevoflurane or desflurane. Currently, FESS is most often performed using total intravenous anaesthesia (TIVA) which is by majority of anaesthesiologists believed to reduce the intraoperative blood loss compared to general anaesthesia using volatile anaesthetics, but current literature provides conflicting findings in this area if the sort of anaesthetic used influences quality of the surgical field.

Interventions

DRUGRemifentanil

a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level

every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes

Sponsors

Medical University of Silesia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* written consent to participate in the study * written consent to undergo functional endoscopic sinus surgery under general anaesthesia * ASA (American Society of Anesthesiologists) I-III

Exclusion criteria

* age under 18 years old * allergy to propofol * pregnancy * any anatomical malformation making SE measurement impossible * necessity of administration of vasoactive drugs

Design outcomes

Primary

MeasureTime frameDescription
blood loss postoperativelyend of operation,' assessmentthe investigators will measure the amount of blood loss in the suction bag in millilitres (ml) using a syringe after operation of FESS is completed

Secondary

MeasureTime frameDescription
heart rate stability intraoperativelyintraoperative assessmentthe investigators will measure heart rate during TIVAevery 5 minutes up to the end of the operation
SPI-guided pain perception intraoperativelyintraoperative assessmentThe investigators will measure SPI values and adjust infusion speed of remifentanyl, in the case of delta SPI\>15 the speed of remifentanyl infusion will accelerate by 50%, intraoperatively, every 1 minute, up to the end of the operation
condition of surgical fieldintraoperative assessmentthe surgeon will assess the quality of surgical field using BBS when the operation of FESS
total consumption of remifentanilend of operation assessmentThe investigators will measure the consumption of remifentanyl intraoperatively
concentration of desflurane in end-expiratory gasintraoperative assessmentThe investigators will measure the concentration of desflurane in end-expiratory gas intraoperatively
concentration of sevoflurane in end-expiratory gasintraoperative assessmentThe investigators will measure the concentration of sevoflurane in end-expiratory gas intraoperatively
total consumption of propofolend of operation assessmentThe investigators will measure the consumption of propofol intraoperatively

Countries

Poland

Contacts

Primary ContactMichał J Stasiowski, MD
mstasiowski.anest@gmail.com696797922
Backup ContactLech Krawczyk, Ph. Dr
lech.kraw@gmail.com323682341

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026